Brands, Medical Use, Clinical Data
- Nootropic Agents
- Capsules (extended-release)
Brands / Synonyms
Galantamin; Galanthamine; Galanthamine base; Galanthamine hydrobromide; Jilkon; Lycoremin; Lycoremine; Razadyne; Reminyl; Reminyl
For the treatment of mild to moderate dementia of the Alzheimer's type.
Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process.
Mechanism of Action
Galantamine's proposed mechanism of action involves the increase of the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.
LD50=75 mg/kg (rat)
Biotrnasformation / Drug Metabolism
REMINYL® (galantamine hydrobromide) is contraindicated in patients with known
hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.